For Healthcare professionals
DigiStain – the UK’s First Breast Cancer Risk Profiling Technology
Digistain for Healthcare professionals provides easy-to-read reporting and clear actionable information to help determine the best course of treatment and indeed whether cytotoxic therapy in addition to hormone therapy is required.
Digsitain demonstrated equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests. In a double-blinded study with over 840 hormone-positive early stage breast cancer patients.
It is based on a mature, sensible approach using well-established analytical technology for chemical analysis that until today has not been used for cancer patient risk scoring.
Risk Actionable Information in Under 1 Hour
Clinical Evidence: Equivalent To Gold Standard NGS Solutions
Mammaprint
Prosigna
Digistain
In a double-blinded study with over 840 hormone-positive early stage breast cancer patients Digsitain demonstrated unequivocal equivalence to the leading NICE approved Next-Generation-Sequencing (NGS) tumour profiling tests
Digistain in Action

Supported by:




Subscribe to leading news and insights
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.